Arcturus Therapeutics Holdings Inc. (ARCT): Trading Report of Monday, June 15


Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) changes shares on Monday trading session, with a change of 16.68% or $5.49 shares. The trading starts at $33.36 and closed at $32.92 throughout the day. The trading session low price was $33.30 and day high was $39.00 on Monday, June 15. After the session, the Healthcare sector daily volume shifted to 1.05 million while its average volume is 656.16K. In other hand, the ARCT market cap reached to $784.72M. While, its current target price is $38.41 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 28.81% and down -7.38% for month. Its quarterly performance was 214.58% above, while its half year performance is up 257.64%. ARCT yearly performance stood at positive 504.88% and rise 253.36% for year-to-date. Current recommendation for Arcturus Therapeutics Holdings Inc. is 1.80.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. ARCT EPS (TTM) for 12-month is -2.39. EPS for this year is 0.50%, while for the next year its value is -1.14. Its EPS Q/Q reached 1.30%. It has an EPS of 33.70% up for past five years.

Let’s take a look on the analyst recommendations on ARCT for the current month and previous month. For the current month, 7 of 9 analysts recommend stock as Buy while 0 as Sell, 1 as overweight, 0 as underweight and 1 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $18.00-$69.00. Average target price for ARCT was reached at $51.00.

ARK Investment Management, LLC, FMR, LLC and DFPG Investments, Inc. are the top three holders in Arcturus Therapeutics Holdings Inc. (ARCT) stock. On Mar 30, 2020, ARK Investment Management, LLC has 1.56 million shares which valued 21.26 million. On Mar 30, 2020, FMR, LLC owned 0.4 million shares which valued at 5.44 million. On Mar 30, 2020, DFPG Investments, Inc. has a total of 0.32 million shares which valued at 4.31 million. In the end, DFPG Investments, Inc. have 1.55% shares outstanding of Arcturus Therapeutics Holdings Inc. (ARCT) on Mar 30, 2020. The insider ownership moved to 14.60% and institutional holding shifted to 24.00%.

The company posted an EPS (TTM) of -2.39. According to the most recent quarter report on (Jun 2020), 7 analysts estimated an average EPS of -0.61, while -0.08 EPS posted a year ago period. Analyst Estimated EPS for ARCT published in the report was -0.72–0.4 during the same period. Comparing with last year, the average estimated EPS was -0.08 which is higher than -0.67 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for ARCT rise 127.16% for period of 200 days. SMA for 50 days was 16.96% which is showing green signal, while SMA-20 was -7.63%. The moving average value for Arcturus Therapeutics Holdings Inc. (ARCT) is 20.05 and 40.36 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in ARCT stock. On Jun 12, Kummerfeld Keith C, See Remarks, bought 450 trading shares at the cost of $33.33, which valued at 14999.0. On Jun 10, Payne Joseph E, President and CEO, bought 1,000 shares at the cost of $31.69, with total shares of 1,475,097. On Jun 10, SASSINE ANDY, Chief Financial Officer, bought 5,000 shares at the cost of 29.74. After this transaction, SASSINE ANDY total shares reached to 273,245 which valued at 0.15 million.